QDEL — QuidelOrtho Corporation stock price, charts and financials

QT38QuidelOrtho Corporation

QuidelOrtho Corporation (NASDAQ: QDEL) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
12.63
+0.34+2.81%
QDELQT38QuidelOrtho Corporation·NASDAQ
12.63+2.81%
Earnings
Up 2.8% — Reported earnings — EPS missed by 111%, revenue missed by 7%.
High confidence
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-17.85Insider Own20.19%Shs Outstand68.19MPerf Week-26.71%
Market Cap837.73MForward P/E5.14EPS next Y2.39Insider Trans0.17%Shs Float67.38MPerf Month-29.53%
Enterprise Value1.22BPEG0.00EPS next Q-Inst Own-Short Float17.52%Perf Quarter14.11%
Income-1.05BP/S0.31EPS this Y110.32%Inst Trans-Short Ratio5.29Perf Half Y-57.16%
Sales2.67BP/B0.47EPS next Y29.79%ROA-18.34%Short Interest11.80MPerf YTD-56.97%
Book/sh-P/C-EPS next 5Y-16.39%ROE-55.30%52W High36.57 -65.46%Perf Year-47.57%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-16.16%52W Low10.19 23.89%Perf 3Y-85.26%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-5.80% 10.43%Gross Margin44.60%Volatility7.57% 6.18%Perf 5Y-91.31%
Dividend TTM-EV/Sales0.46EPS Y/Y TTM41.55%Oper. Margin-30.67%ATR (14)1.38Perf 10Y-47.12%
Dividend Ex-Date-Quick Ratio0.76Sales Y/Y TTM-4.49%Profit Margin-39.20%RSI (14)29.10Recom2.73
Dividend Gr. 3/5Y-Current Ratio1.39EPS Q/Q-105.41%SMA20-26.95%Beta0.63Target Price12.25
Payout0.00%Debt/Eq0.29Sales Q/Q-10.53%SMA50-21.41%Rel Volume2.85Prev Close12.29
Employees6,500LT Debt/Eq1.37EarningsAug 06SMA200-40.25%Avg Volume1.71MPrice12.63
IPO DateFeb 01, 1991Option/ShortYes / YesEPS/Sales Surpr.-111.20% -6.83%Net Debt/EBITDA-0.77Volume4,888,564Change2.81%
Analyst Ratings
DateActionAnalystRatingTarget
May-07-26ReiteratedUBSNeutral$17$12
May-07-26DowngradeJefferiesBuyHold$13
Apr-10-26ReiteratedUBSNeutral$30$17
Feb-12-26ReiteratedUBSNeutral$35$30
Jan-21-26ReiteratedUBSNeutral$35
Oct-07-25DowngradeCitigroupBuyNeutral
May-08-25UpgradeJefferiesHoldBuy
Dec-11-24UpgradeCitigroupNeutralBuy
Sep-19-24ReiteratedUBSSell
Sep-05-24ReiteratedCraig-HallumHold
Latest News
Aug-07-26
Aug-06-26
Aug-05-26
Aug-03-26
Jul-24-26
Jul-23-26
Jul-20-26
Jul-15-26
Jul-08-26
Company

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/28/2025
FY 2024
12/29/2024
FY 2023
12/31/2023
FY 2022
1/1/2023
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,6752,7302,783
Cost of Goods Sold Incl. D&A1,4811,4561,496
Gross Profit1,1931,2741,287
Selling, General and Administrative Excl. Other770746767
Research and Development182186219
Other Operating Expense1,0611,2612,261
Operating Income-820-919-1,961
Interest Expense195178188
Unusual Expense
Non-Operating Income (Expense)-15-1118
Net Income Before Taxes-1,029-1,108-2,131
Income Taxes1824-79
Consolidated Net Income-1,049-1,132-2,052
Net Income From Continuing Operations-1,049-1,132-2,052
Net Income-1,049-1,132-2,052
EPS (Recurring)-15.44-16.69-30.54
EPS (Basic, Before Extraordinaries)-15.44-16.69-30.54
EPS (Diluted)-15.44-16.69-30.54
EBITDA-499-488-1,490
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
Price To Sales Ratio0.320.731.07
Gross Margin44.6046.6746.25
Operating Margin-30.65-33.66-70.46
Net Margin-39.21-41.47-73.73
Shares Outstanding686867
Market Capitalization8591,9922,965
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$39.19$30.93$22.67$14.41$6.15 Close Price0.00K164.66K329.33K493.99K658.65KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Hanson Bryan MichaelEVP Global Port. Mgmt & MktingJul 01 '26Option Exercise0.005,79709,867Jul 02
WIDDER KENNETH JDirectorJun 06 '26Option Exercise0.001,18300Jun 09
POLAN MARY LAKE PH DDirectorJun 06 '26Option Exercise0.0097300Jun 09
BUECHLER KENNETH FDirectorJun 06 '26Option Exercise0.002,15600Jun 09
Michael Edward L.DirectorJun 06 '26Option Exercise0.001,25200Jun 09
Michael Edward L.DirectorMay 29 '26Option Exercise0.006,82900Jun 02
Strobeck MatthewDirectorMay 29 '26Option Exercise0.006,82900Jun 02
WIDDER KENNETH JDirectorMay 29 '26Option Exercise0.006,82900Jun 02
POLAN MARY LAKE PH DDirectorMay 29 '26Option Exercise0.006,82900Jun 02
BUECHLER KENNETH FDirectorMay 29 '26Option Exercise0.006,82900Jun 02
Chiminski John RDirectorMay 29 '26Option Exercise0.006,82900Jun 02
Huennekens R ScottDirectorMay 29 '26Option Exercise0.006,82900Jun 02
Wilkins Joseph D Jr.DirectorMay 29 '26Option Exercise0.006,82900Jun 02
RHOADS ANN DDirectorMay 29 '26Option Exercise0.006,82900Jun 02
Dilsaver Evelyn SDirectorMay 29 '26Option Exercise0.006,82900Jun 02
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.